<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-OCH-12002643</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2012-10-31</date_registration>
      <primary_sponsor>Institute of Hematology Peking University, People's Hospital,</primary_sponsor>
      <public_title>Autologous stem cell transplantation for patients with favorable- and intermediate-risk acute myeloid leukemia in first complete remission</public_title>
      <acronym>ASCT for AML</acronym>
      <scientific_title>Autologous stem cell transplantation for patients with favorable- and intermediate-risk acute myeloid leukemia in first complete remission</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2008-01-01</date_enrolment>
      <type_enrolment />
      <target_size>Favorable-risk AML:50;Intermediate-risk AML:40;</target_size>
      <recruitment_status>Completed</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=6909</url>
      <study_type>Observational study</study_type>
      <study_design>Cohort study</study_design>
      <phase>III (Phase III study)</phase>
      <hc_freetext>Acute myeloid leukemia</hc_freetext>
      <i_freetext>Favorable-risk AML:Autologous stem cell transplantation;Intermediate-risk AML:Autologous stem cell transplantation;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Huan Chen</firstname>
        <middlename />
        <lastname />
        <address>Institute of Hematology Peking University, People's Hospital, No.11 Xizhimen south Street, Beijing China</address>
        <city />
        <country1 />
        <zip>100044</zip>
        <telephone>+86 10 88324952</telephone>
        <email>chenhuan@cssc.net.cn</email>
        <affiliation>Institute of Hematology Peking University, People's Hospital</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Xiao-jun Huan</firstname>
        <middlename />
        <lastname />
        <address>Institute of Hematology Peking University, People's Hospital, No.11 Xizhimen south Street, Beijing China</address>
        <city />
        <country1 />
        <zip>100044</zip>
        <telephone>+86 10 88326006</telephone>
        <email>huangxiaojun@bjmu.edu.cn</email>
        <affiliation />
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. Patients with de novel AML in favorable and intermediate-risk group younger than 60 years old;
2. Peripheral blood stem cell harvesting was started if patients reached CR1 and MRD level was less than 0.1% without LAIPs after 1 to 2 courses of induction therapy and at least 2-3 courses of consolidation therapy including high-doses Ara-C;
3. ECOG=0,1.</inclusion_criteria>
      <agemin>8</agemin>
      <agemax>60</agemax>
      <gender>Male</gender>
      <exclusion_criteria>1.Secondary AML, &gt;60 years old;
2.AML in high-risk cytogenetic group;
3. to reach CR1 with more than 2 courses of induction;
4. &gt;CR1 or MRD level &gt;0.1% (including RQ-PCR test )and with FCM-LAIPs;
5.ECOG &gt;=2.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Relaose-free survival;Overall survival (OS);</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>association between MRD and relapse;safety of ASCT;Factors associated with relapse;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Clinical Research Foundation of Medical Doctor Association (grant No. 812090) and National Public Health Grant Research Foundation (grant No. 201202017).</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Not approved</status>
        <approval_date>2013-08-26</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>